Avidity Biosciences ( (RNA) ) has provided an announcement.
Avidity Biosciences is making strides in precision cardiology with its development of AOC 1072 and AOC 1086, designed to target rare genetic cardiomyopathies by delivering siRNA directly to the heart muscle. These candidates demonstrated significant gene knockdown and safety in preclinical studies. The company also revealed next-generation RNA technology innovations promising enhanced delivery and durability, which could revolutionize treatment options for genetic cardiac diseases.
Find detailed analytics on RNA stock on TipRanks’ Stock Analysis page.
